Liza Laws, Author at Labiotech.eu

News and Trends 5 Jul 2022

Positive news from trial for drug to treat major depressive disorder

A company working on treatments for people with mental health issues has had positive feedback from the development program of an anti-depressant targeting major depressive disorder (MDD). ANeuroTech has just announced that after a successful pre-Investigational New Drug Application (IND) meeting, the US Food and Drug Administration (FDA) has given positive feedback on its […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

AstraZeneca adds to its treatments for blood cancer with $100M deal

AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the […]

July 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 4 Jul 2022

Nanoparticle can kill cancer cells and aid muscle relaxation

A nanoparticle that is both a nanoheater and a nanothermometer at the same time has been developed by researchers at a Japanese university. The university said this is a significant development that not only aids muscle relaxation, but it can also kill cancer cells. Satoshi Arai and colleagues at Kanazawa University have successfully showed that […]

July 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Jul 2022

New home for wet lab incubator in bid to help biotech start-ups and promote life sciences

A lab to bring together the hive minds of those addressing the future challenges in healthcare, including biotech start-ups, is set to open at Discovery Park, Kent, U.K. Barclays has selected the location as the home for its latest Eagle Lab, which will open later this year. The labs are a growing national network currently at […]

July 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Jul 2022

Progress for hearing preservation trial after Australian approval granted

Approval has been granted by the Australian authorities to allow a French company to progress with a clinical trial testing cochlear implants. Montpellier-based Sensorion will start its proof of concept trial of SENS-401, a drug candidate that aims to protect and preserve inner ear tissue from damage. Sensorion is a biotech company specializing in the […]

July 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Jul 2022

Companies come together in fight against Dengue Fever

A vaccine to treat dengue fever, the mosquito-borne disease, is the end goal of two companies who have signed an agreement to produce and commercialize a lead candidate in the fight against the disease. Emergex Vaccines Holding Limited, a clinical-stage biotech company, recently announced that it has agreed a collaboration with the Molecular Biology Institute […]

July 1, 2022 - 4 minutesmins - By Liza Laws

News and Trends 1 Jul 2022

License submitted to FDA for drug to help those with large B-cell lymphoma

A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […]

July 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

LG Chem renews license triggering $2M payment to Avacta

South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal fee to UK-based oncology drug company Avacta Group plc. of $2 million. Avacta develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms. Under the terms of the agreement, LG Chem has the exclusive rights to develop […]

June 30, 2022 - 2 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […]

June 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

Funding doubled for company working on breakthrough auto-immune disease therapeutics

A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it has almost doubled its initial funding from two companies. The initial funding for Ermium Therapeutics of €6.3 million ($6.57 million) now stands at €12.3 million ($12.83 million) and has been supplied by Kurma Partners and Fountain Healthcare Partners. Ermium discovers […]

June 30, 2022 - 3 minutesmins - By Liza Laws

decentralized trial virtual clinical trial

News and Trends 29 Jun 2022

Global call for scientists and inventors to form new startup

A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […]

June 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jun 2022

Drug for childhood arthritis gets expanded approvals in the EU

A drug that can reduce the risk of flare and disease activity in children with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) has been approved based on data from a clinical trial. The JUNIPERA trial, showing that Cosentyx (secukinumab) reduced the risk of flare and disease activity compared to placebo over two years in pediatric patients with […]

June 29, 2022 - 4 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Positive news from trial for drug to treat major depressive disorder

AstraZeneca adds to its treatments for blood cancer with $100M deal

Nanoparticle can kill cancer cells and aid muscle relaxation

New home for wet lab incubator in bid to help biotech start-ups and promote life sciences

Progress for hearing preservation trial after Australian approval granted

Companies come together in fight against Dengue Fever

License submitted to FDA for drug to help those with large B-cell lymphoma

LG Chem renews license triggering $2M payment to Avacta

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

Funding doubled for company working on breakthrough auto-immune disease therapeutics

Global call for scientists and inventors to form new startup

Drug for childhood arthritis gets expanded approvals in the EU

Subscribe to our newsletter to get the latest biotech news!